Laurel Wealth Advisors Inc. Acquires 21,010 Shares of Novartis AG (NVS)
Laurel Wealth Advisors Inc. increased its holdings in Novartis AG (NYSE:NVS) by 101.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 41,642 shares of the company’s stock after purchasing an additional 21,010 shares during the period. Novartis makes up 0.8% of Laurel Wealth Advisors Inc.’s portfolio, making the stock its 25th biggest position. Laurel Wealth Advisors Inc.’s holdings in Novartis were worth $3,144,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the stock. Winthrop Partners WNY LLC bought a new stake in Novartis during the first quarter worth about $100,000. Gables Capital Management Inc. bought a new stake in Novartis during the first quarter worth about $103,000. Archford Capital Strategies LLC bought a new stake in Novartis during the first quarter worth about $149,000. Quad Cities Investment Group LLC bought a new stake in Novartis during the second quarter worth about $139,000. Finally, Private Capital Group LLC grew its stake in Novartis by 410.8% during the first quarter. Private Capital Group LLC now owns 2,467 shares of the company’s stock worth $204,000 after buying an additional 1,984 shares during the last quarter. 10.95% of the stock is owned by hedge funds and other institutional investors.
In other news, major shareholder Bioventures Ltd Novartis sold 12,460 shares of the stock in a transaction that occurred on Wednesday, July 25th. The shares were sold at an average price of $3.84, for a total transaction of $47,846.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have sold 81,322 shares of company stock worth $290,796 over the last three months. 0.01% of the stock is owned by insiders.
Novartis (NYSE:NVS) last released its quarterly earnings results on Wednesday, July 18th. The company reported $1.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.27 by $0.02. Novartis had a net margin of 27.06% and a return on equity of 16.05%. The business had revenue of $13.16 billion for the quarter, compared to analysts’ expectations of $12.93 billion. During the same period in the prior year, the firm earned $1.22 earnings per share. Novartis’s revenue was up 7.5% compared to the same quarter last year. equities analysts anticipate that Novartis AG will post 5.17 EPS for the current fiscal year.
Several brokerages have weighed in on NVS. Zacks Investment Research raised shares of Novartis from a “hold” rating to a “buy” rating and set a $95.00 price objective on the stock in a research note on Tuesday. BNP Paribas raised shares of Novartis from an “underperform” rating to a “neutral” rating in a research note on Tuesday, September 11th. ValuEngine raised shares of Novartis from a “sell” rating to a “hold” rating in a research note on Wednesday, September 12th. Citigroup raised shares of Novartis from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 11th. Finally, Exane BNP Paribas raised shares of Novartis from an “underperform” rating to a “neutral” rating in a research note on Tuesday, September 11th. Eleven research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Novartis currently has a consensus rating of “Hold” and a consensus price target of $86.90.
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.
Featured Article: New Google Finance Tool and Screening Stocks
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.